scholarly journals Autologous Platelet-Rich Plasma Eye Drops for the Treatment of Post-LASIK Chronic Ocular Surface Syndrome

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Jorge L. Alio ◽  
Alejandra E. Rodriguez ◽  
Ahmed A. Abdelghany ◽  
Renan F. Oliveira
Keyword(s):  
Ocular Surface ◽  
Platelet Rich Plasma ◽  
Laser In Situ Keratomileusis ◽  
Eye Drops ◽  
Conjunctival Hyperemia ◽  
Eye Symptoms ◽  
Autologous Platelet Rich Plasma ◽  
Autologous Platelet ◽  
Punctate Keratitis

Purpose. To evaluate the efficacy of autologous platelet-rich plasma (E-PRP) eye drops for the treatment of chronic ocular surface syndrome (OSS) following laser in situ keratomileusis (LASIK).Methods. This prospective interventional consecutive clinical study include 156 eyes of 80 patients affected by post-LASIK chronic OSS who were treated with autologous E-PRP 6 times a day as monotherapy for 6 weeks.Results. Dry eye symptoms improved in 85% of the cases. A decrease in at least one quadrant to total disappearance on CFS was observed in 89.6% of the patients who had positive CFS before treatment. Three eyes presented severe punctate keratitis (1.9%) at baseline, all of which healed completely. Conjunctival hyperemia improved in 93.3% of the patients with previous signs of ocular surface inflammation. There was a significant improvement in logMAR CDVA from 0.14 ± 0.19 to 0.06 ± 0.12 (p=0.000), and 74 (71.4%) eyes improved at least 1 line in CDVA.Conclusion. Monotherapy with autologous E-PRP is a well-tolerated, safe, and effective treatment for the management of post-LASIK ocular surface syndrome.Precis. Monotherapy with autologous platelet-rich plasma eye drops has been shown to be an adequate option for the treatment of post-LASIK chronic ocular surface syndrome. This trial is registered withNCT03322917.

scholarly journals Comparison of treatment efficacy between 100% platelet-rich plasma and 100% serum eye drops in moderate-to-severe dry eye disease: a randomised controlled trial protocol

BMJ Open ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. e048479
Author(s):  
Passara Jongkhajornpong ◽  
Pawin Numthavaj ◽  
Thunyarat Anothaisintawee ◽  
Kaevalin Lekhanont ◽  
Gareth McKay ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Platelet Rich Plasma ◽  
Controlled Trial ◽  
Dry Eye Disease ◽  
Autologous Serum ◽  
Eye Disease ◽  
Eye Drops ◽  
Department Of Ophthalmology ◽  
Autologous Platelet

IntroductionDry eye disease (DED) is a common eye problem. Although the disease is not fatal, it substantially reduces quality of life and creates a high economic burden, especially in patients with moderate-to-severe DED. Several biological tear substitutes (eg, autologous serum (AS), autologous platelet-rich plasma (APRP) and autologous platelet lysate) could effectively improve dry eyes. However, evidence on their comparative efficacy is controversial. This study aims to compare the efficacy of 100% APRP with 100% AS eye drops in patients with moderate-to-severe DED.Methods and analysisThe study is a single-centre, double-blinded randomised, parallel, non-inferiority trial. One hundred and thirty patients with moderate-to-severe DED, aged 18–70 years will be recruited from outpatient clinic, Department of Ophthalmology, Ramathibodi Hospital, Bangkok from February 2021 to January 2023. Patients will be randomised to receive either 100% APRP or 100% AS eye drops (1:1 ratio) for 4 weeks. The primary outcomes are ocular surface disease index (OSDI) and ocular surface staining (OSS) evaluated using the Oxford scale. Secondary outcomes are fluorescein break-up time, Schirmer’s I test, meibomian gland parameters and adverse events. Other measured outcomes include best-corrected visual acuity, intraocular pressure and compliance.Ethics and disseminationThe study protocol and any supplements used in conducting this trial have been approved by the Ethics Committee of Faculty of Medicine, Ramathibodi Hospital, Mahidol University (MURA2020/1930). Informed consent will be obtained from all patients before study entry. Results will be presented in peer-reviewed journals and international conferences.Trial registration numberNCT04683796.

Treatment of Ocular Surface Syndrome After LASIK With Autologous Platelet-rich Plasma

2007 ◽  
Vol 23 (6) ◽  
pp. 617-619 ◽  
Author(s):  
Jorge L Alio ◽  
Silvia Pastor ◽  
Jose Ruiz-Colecha ◽  
Alejandra Rodriguez ◽  
Alberto Artola
Keyword(s):  
Ocular Surface ◽  
Platelet Rich Plasma ◽  
Autologous Platelet Rich Plasma ◽  
Autologous Platelet

scholarly journals Autologous platelet-rich plasma eye drops accelerate re-epithelialization of post-keratoplasty persistent corneal epithelial defects

2019 ◽  
Vol 14 (2) ◽  
pp. 131
Author(s):  
MozhganRezaei Kanavi ◽  
Shaban Alizadeh ◽  
Sahar Balagholi ◽  
Alireza Baradaran-Rafii ◽  
Siamak Delfaza-Baher ◽  
...  
Keyword(s):  
Platelet Rich Plasma ◽  
Eye Drops ◽  
Corneal Epithelial ◽  
Autologous Platelet Rich Plasma ◽  
Autologous Platelet

Treatment with platelet-rich plasma of surgically related dormant corneal ulcers

2018 ◽  
Vol 28 (5) ◽  
pp. 515-520 ◽  
Author(s):  
Jorge L Alio ◽  
Alejandra E Rodriguez ◽  
Pablo De Arriba ◽  
Sandra Gisbert ◽  
Ahmed A Abdelghany
Keyword(s):  
Platelet Rich Plasma ◽  
Corneal Edema ◽  
Rank Test ◽  
Eye Drops ◽  
Corneal Surgery ◽  
Corneal Ulcers ◽  
Signed Rank Test ◽  
Autologous Platelet Rich Plasma ◽  
A Prospective Study ◽  
Autologous Platelet

Purpose: To assess the effectiveness of autologous platelet-rich plasma for the treatment of dormant corneal ulcers secondary to corneal surgery and unresponsive to conventional treatment. Setting: VISSUM, Ophthalmology Institute of Alicante, Alicante, Spain. Design: Prospective nonrandomized, observational consecutive study. Methods: A total of 44 eyes of 28 patients with dormant corneal ulcers secondary to corneal surgery were included in a prospective study and treated with autologous platelet-rich plasma during 6 weeks. Wilcoxon signed-rank test was used to compare the effect of the treatment. Results: In all, 28 patients (65.1%) improved their visual acuity at least one line in Snellen chart, 26 (59.09%) had a decrease in the size of the ulcer or even a total closure, and 40 (90.9%) experienced an improvement in their symptoms. The results are also provided for the four groups of patients (keratoplasty, refractive surgery, cross-linking, and chronic postsurgical corneal edema). Conclusion: Platelet-rich plasma eye drops shows to be a good option for the treatment of dormant corneal ulcers secondary to corneal surgery.

Sign in / Sign up

Export Citation Format

Share Document